Stockscreener 앱 받기
2.10
0.94%
-0.02
전일 마감가:
$2.12
열려 있는:
$2.12
하루 거래량:
480.92K
Relative Volume:
0.50
시가총액:
$121.59M
수익:
$54.77M
순이익/손실:
$15.24M
주가수익비율:
8.6207
EPS:
0.2436
순현금흐름:
$7.24M
1주 성능:
-4.55%
1개월 성능:
-17.32%
6개월 성능:
-17.65%
1년 성능:
-26.06%
1일 변동 폭
$2.05
$2.1565
1주일 범위
$2.05
$2.23
52주 변동 폭
$1.80
$3.08
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.10 | 121.59M | 54.77M | 15.24M | 7.24M | 0.2436 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors - Yahoo! Finance Canada
Spero Therapeutics outlines its antibiotic pipeline as investors track regulatory progress - ad-hoc-news.de
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell Microcap Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Form 4 Spero Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO) - TradingView
Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO) - TradingView
Spero Therapeutics Expands Stock Incentive Plan and Authorization - The Globe and Mail
Spero Therapeutics (SPRO) director awarded RSUs and 20,000-share option - Stock Titan
Spero Therapeutics (SPRO) director receives RSU and stock option awards - Stock Titan
Spero Therapeutics (SPRO) director receives 10,000 RSUs and 20,000-share option grant - Stock Titan
Spero Therapeutics (SPRO) director awarded RSUs and stock options - Stock Titan
Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options - Stock Titan
Equity awards to Spero (NASDAQ: SPRO) director Scott Jackson - Stock Titan
Spero Therapeutics (SPRO) director receives RSU and 20,000-share option grant - Stock Titan
Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan - Stock Titan
SPRO Forecast — Price Target — Prediction for 2027 - TradingView
Spero Therapeutics (SPRO) Slips 3.81% as Selling Pressure Tests Key Support LevelsSystematic Flow - dars.gov.et
Spero Therapeutics Inc (SPRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
FDA clears Spero (NASDAQ: SPRO) oral Utebzi antibiotic for complicated UTIs - Stock Titan
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Yahoo Finance
Spero Therapeutics Inc (NASDAQ: SPRO) Share Price, SPRO Stock News, SPRO Share Price & Updates - Kalkine
US FDA approves GSK's oral antibiotic for drug-resistant UTIs - Reuters
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics Stock: Antibiotic Development In Focus - Kalkine Media
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections - TradingView
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics Inc (SPRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spero Therapeutics Inc (SPRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AlTi Global And 2 Other Promising Penny Stocks To Watch - simplywall.st
Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US - Quiver Quantitative
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - GlobeNewswire
FDA approves first oral carbapenem for complicated UTIs in adults - Stock Titan
GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections - Moomoo
GSK, Spero Therapeutics Gain U.S. Approval for Utebzi - marketscreener.com
SPRO Stock Slumps As Volatility Grips Small-Cap Biotech - timothysykes.com
Spero Therapeutics Approaches Key FDA Decision For Tebipenem HBr In CUTIs - RTTNews
Spero Therapeutics Inc (SPRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spero Therapeutics Inc (SPRO) Institutional Confidence - TradingKey
Spero Therapeutics Inc (SPRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spero Therapeutics Inc (SPRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Spero Therapeutics Inc (SPRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Spero Therapeutics Stock (US85208T1079): Quiet session keeps focus on fundamentals and pipeline - AD HOC NEWS
SPRO Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentSlow Growth Warning - dars.gov.et
SPRO News | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold) - Seeking Alpha
Spero Therapeutics Inc. Q1 2026 Earnings: Better-Than-Expected Loss Provides Little Respite as Shares FallMargin Guidance - dars.gov.et
Spero Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls Amid Lack of Revenue - newsline.com
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):